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Brief Correspondence
Overexpression of Placental Growth Factor in Stromal Cells from
Benign Prostatic Hyperplasia: Another Piece in the Puzzle?
Conor M. Devlin a,y, Fiona M. Frame a, Leanne K. Archer a, Vincent M. Mann b,c, Hannah Walker a,
Matthew S. Simms c, Daniel M. Berney d, Anne T. Collins a, Norman J. Maitland a,b,*
Lower urinary tract symptoms associated with benign
prostatic hyperplasia (BPH) have a European prevalence of
24% and are a significant economic burden for the society
(>£200 million annually in the UK) [1].
BPH is a disease of ageing, the incidence and prevalence
of which increase as men get older. However, the exact
cause(s) remains disputed despite much research. Aetiolo-
gical studies have focussed on inflammatory processes
within the prostate, which lead to growth factor (GF)
production, stem cell activation, and cellular proliferation
[2].
The 5a reductase inhibitors, which target the androgen
signalling axis in prostate cells, decrease the impact of
androgen receptor on cell proliferation in BPH [3]. Whilst
symptomatic improvement and disease regression are
observed, a significant treatment time is required and a
proportion of patients fail treatment and require surgery.
These long response times imply that the true driver(s)
of the disease may not be targeted by this treatment; that is,
what is the overall dependence of BPH on androgens? Thus,
targeting of the wrong “driver” cell population and indirect
activation of AR via intermediate intracellular pathways
through inflammatory signalling could explain equally the
variable success of 5aRIs.
Since the characteristic cellular overgrowths, of both
epithelial and stromal components, in BPH are dependent
on either autocrine or paracrine stimulation by GF, we
sought to survey a fuller range of human GF genes for their
potential influence on BPH. GF mRNA array (Qiagen, Hilden,
Germany) analyses were performed on RNA from uncultured
prostate cell subpopulations, luminal cells (LCs; EpCAM+/
CD49+), committed basal cells (CBs; EpCAM+/CD24+), and
stromal cells (StCs; EpCAM–/Vimentin+) freshly purified
from BPH tissue. The direct approach, more closely
applicable to in vivo conditions, was prompted by earlier
studies [4], which revealed a number of cell culture artefacts
stimulated by GF in culture media. Separation is important,
since whole tissue homogenates can mask the origin and
impact of a GF or cytokine, and dilute the magnitudes of
differential RNA expression [5].
GF mRNA expression was significantly higher within the
StC population than in the epithelial layer (LCs and CBs), for
example, fibroblast growth factors 2 and 7 and insulin
growth factor 1, as previously demonstrated for BPH.
However, the GF with the highest expression disparity
was placental growth factor (PlGF; Fig. 1A, and Supplemen-
tary Fig. 3 and 4), a member of the vascular endothelial
growth factor (VEGF) family that binds exclusively to VEGF
receptor 1 (VEGFR1) [6], which had previously shown
negligible associations with BPH pathology.
Other VEGF (A and C) family GFs did not demonstrate
significant expression upregulation. However, whole tissue
homogenates consistently expressed both active isoforms of
PlGF protein (Fig. 1B), together with VEGFR1 in 66% of
samples (Fig. 1B-iii), implying that some heterogeneity is
nevertheless apparent within different BPH disease pro-
cesses.
Immunocytochemical analysis of uncultured, fractionat-
ed, paraformaldehyde (PFA)-fixed individual cell popula-
tions was next carried out for PlGF and VEGFR1 (Fig. 1C and
Supplementary Fig. 5). In agreement with the GF array data,
higher PlGF protein expression is seen in fixed StCs than in
LCs and CBs. These high levels of expression suggest that
stromal PlGF is released into the extracellular matrix to
propagate its effect on other cell types. In PFA-fixed cells,
VEGFR1 expression was strong in all prostate cell subtypes.
When we immunostained formalin-fixed, paraffin-embed-
ded BPH tissue (tissue microarrays—24 patients, from the
Orchid Research tissue bank, Barts Hospital, London, UK),
PlGF expression was observed in LCs and StCs, with the
highest expression in the luminal epithelia (Fig. 1D and
Supplementary Fig. 6), unlike the freshly PFA-fixed cells. We
validated this observation by staining frozen fixed BPH
sections that also demonstrated high PlGF expression in LCs
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Fig. 1 – Placental growth factor (PlGF) expression in uncultured benign prostatic hyperplasia (BPH). (A) Quantitative real-time polymerase chain
reaction (qRT-PCR) analysis of mRNA fold expression for PlGF and vascular endothelial growth factor (VEGF) A and C in fractionated and uncultured
stromal versus luminal cells from fresh BPH tissue (n = 6). A scatter plot of expressed mRNA was generated from Qiagen (Hilden, Germany) web-based
PCR-array data analysis software. The X axis represents the log expression of mRNA GFs in the combined (n = 6) stromal cell samples, whilst the Y axis
represents the log expression of mRNA GFs in the combined (n = 6) luminal cell samples. Three points on the graph are shown, which represent PlGF,
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(Fig. 1E), so paraffin embedding of tissue had not affected
the PlGF expression pattern. This contrast in PlGF location
between isolated cells and fixed tissue arrays could be the
result of epitope masking or destruction during processing,
but could equally be due, in part, to hypoxia-induced
expression of PlGF during the cellular isolation process.
Although a potential artefact, this demonstrates that
hypoxic stress (known to occur in BPH) will drive the
overexpression of PlGF, where it has not been identified
before, or indeed a paracrine effect of the epithelium on the
stroma. Expression of VEGFR1 in the tissue microarrays was
widespread throughout all the cell subtypes, similar to the
Table 1 – Expression of PlGF and VEGFR1 in each cell population in formalin-fixed paraffin-embedded BPH tissue sections on tissue
microarrays (Bart’s Hospital, London).
Sample No. Prostate tissue layer
Luminal Basal Stroma
PlGF VEGFR1 PGF VEGFR1 PlGF VEGFR1
1 ++ ++ – ++ – ++
2 +++ +++ – +++ – ++
3 + +++ – ++ – +
4* – – – – – +++
5 + ++ – – – ++
6 ++ ++ ++ ++ ++
7 – – +++ +++ + +
8 +++ +++ +++ +++ + +
9* – – – – – ++
10 +++ ++ – ++ + +++
11 +++ +++ – +++ + +
12* – – – – – +
13 +++ +++ – +++ + +
14 +++ +++ – – – –
15 ++ ++ – – + +
16 + +++ – +++ ++ ++
17 ++ ++ – ++ ++ ++
18 ++ ++ – ++ + ++
19* – – – – – ++
20 ++ ++ – ++ – +
21 – – ++ ++ – ++
22 +++ +++ – + – ++
23* – – – – – +
24 + ++ – + – ++
BPH = benign prostatic hyperplasia; PlGF = placental growth factor; VEGFR1 = vascular endothelial growth factor receptor 1.
The symbol +++ denotes strong staining, ++ moderate, + weak, and – absent of staining. The strongest and most abundant expression of PlGF in the array was in
the luminal cell layer, with occasional expression in the stroma in nine samples. VEGFR1 expression was higher in all cell population layers than in PlGF
expression, and all samples within the array demonstrated VEGFR1 expression within at least one cell population. Only one stromal sample [14] did not express
the receptor. There was a strong correlation between PlGF expression and VEGFR1 expression within the luminal cell layer. Committed basal cell VEGFR1
expression did not correlate with PlGF expression levels.
aNext to the sample number, indicated that no epithelial layer was present on the tissue section.
VEGFA, and VEGFC. Other GF data points have been removed for clarity; however Supplementary Figures 3 and 4 demonstrate the additional GF
investigated in the array. Data were normalised to RPLPO and Actin beta gene expression. The scatter plot of fold expression differences demonstrated
that PlGF expression was 190T greater in stromal BPH cells than in luminal BPH cells, which was statistically significant (p < 0.05). VEGFA and VEGFC
did not demonstrate significant expression fold changes (p > 0.05). Data analysis of each array cell sample was performed using the SABiosciences PCR
array data analysis centre (Qiagen, Hilden, Germany). Fold expression differences of <2 were considered as not significantly different in expression,
which is shown in the graph by the parallel expression lines, that is, values above the dashed black lines are >2 times that of the control (luminal
cells) and are statistically significant. The solid line represents fold expression that is equal between the control (luminal) and the comparative
(stromal) group. (B) Western blot analysis of PlGF expression (isoforms 1 and 2) and its receptor VEGF receptor 1 (VEGFR1) in unfractionated
homogenised fresh BPH tissue (n = 3). Both isoforms of PlGF were expressed in all patient samples; interestingly, VEGFR1 expression was not seen in
patient (iii), which demonstrated the heterogeneity in BPH pathology. Tubulin and GAPDH were used as loading controls for PlGF and VEGFR1,
respectively. (C) Immunofluorescence analysis of paraformaldehyde-fixed fractioned uncultured cell subpopulations from fresh BPH tissue showing
highest expression of PlGF within stromal cells (red stain, first column) and widespread VEGFR1 expression (red stain, second column) in all cell
populations, particularly luminal cells, suggesting a paracrine influence of stroma on the proliferating epithelial layer. Cytokeratin 18 and vimentin
were controls for luminal and stromal cells, respectively (green stain, third column). Cytokeratin 5 was a control for committed basal cells (red stain,
third column). Nuclei are stained blue (DAPI). These cells were a representation of 100 cells in each well of a chamber slide. Images were captured on
a Zeiss upright 710 confocal microscope (Carl Zeiss Microscopy GmbH, Jena, Germany). The scale bar is 20 mm. (D) Immunohistochemical analysis of
formalin-fixed paraffin-embedded (FFPE) BPH tissue sections from tissue microarrays (Barts Hospital, London, UK) showing the highest expression of
PlGF was within the luminal cell layer (i), which was in contrast to that seen by immunofluorescence. VEGFR1 was expressed within luminal, basal,
and stromal cells (ii). P63 was used as a committed basal cell marker (iii). Sections were stained using ImmPRESS Excel Amplified HRP Polymer
Staining Kit (anti-rabbit IgG kit: MP7601 and anti-mouse kit: MP7602; Vector Laboratories, Peterborough, UK). The scale bar is 100 mm. (E)
Immunohistochemical analysis of fresh frozen BPH tissue section showing the FFPE process did not contribute to the findings of highest expression of
PlGF within the luminal cell layer (i), as this matched with the findings in Figures 1D-i and 1D-ii. P63 was again used as a committed basal cell marker
(iii), and sections were stained using the ImmPRESS Excel Amplified HRP Polymer Staining Kit (Vector Laboratories, Peterborough, UK). The scale bar is
50 mm. GF = growth factor.
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fixed isolated cells. In the tissue arrays, VEGFR1 protein was
most abundant within the StC population. No patient
sample within any of the three cell subpopulations lacked
VEGFR1 expression (Table 1).
The PlGF/VEGFR1 complex can both directly and
indirectly activate pathways involved in angiogenesis,
which follow a number of current disease pathways
hypothesised for BPH. The recruitment of angiogenesis-
competent myeloid bone marrow progenitors to growing
vessel sprouts and collateral blood vessels [7] could be
viewed as the use of stem cells to drive this processes
forward, for example, the role of bone marrow–derived
mesenchymal stem cells described recently by Brennen and
Isaacs [8] in relation to the embryonic reawakening theory
of BPH.
As a response to stress, PlGF recruits monocytes, which
then differentiate into macrophages and foam cells. These
cells then release proinflammatory cytokines such as
interleukin (IL) 6 and IL1b, leading to further recruitment
of angiogenic/inflammatory cells and further secretion of
PlGF [9]. Such a “vicious cycle” of inflammation was
proposed previously by Ficarra et al [2] for BPH. Interest-
ingly, StCs that are activated by PlGF release both FGF2 and
IL8 [9], two factors previously highlighted in the inflamma-
tion cycle linked to the formation of BPH [2]. We therefore
propose a hypoxia/stress cycle induced by PlGF cross
stimulation in BPH promoting prostate growth and also
neovascularisation, important in the expansion of new
tissue. A similar mechanism has been detected (and treated
experimentally with anti-PlGF therapy) between chronic
myeloid leukaemia and bone marrow StCs [10].
This research forms a basis for the investigation into
another piece of the complex BPH puzzle. Further studies on
the impact of PlGF-induced growth on in vitro cultured
primary cells may potentially open a new avenue for the
medical treatment of this disease, since PlGF expression is
highly restricted in normal human adult tissues.
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